Evidence map›Paper›PMID 35846573›Full record

ArticleMolecular therapy. Methods & clinical development2022

Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.

Shilpa Prabhakar, Roberta L Beauchamp, Pike See Cheah, Akiko Yoshinaga, Edwina Abou Haidar, Sevda Lule, Gayathri Mani, Katia Maalouf, Anat Stemmer-Rachamimov, David H Jung and 6 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Molecular therapy. Nucleic acids · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Novel AAV variants with improved tropism for human Schwann cells.Molecular therapy. Methods & clinical development · 2024
    Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Shilpa PrabhakarDepartment of Neurology and Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Roberta L BeauchampCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Pike See CheahDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Center for Molecular Imaging Research, Massachusetts General Hospital, 25 Shattuck St, Boston, MA 02115, USA.
Akiko YoshinagaDepartment of Neurology and Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA.
Edwina Abou HaidarDepartment of Neurology and Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Sevda LuleDepartment of Neurology and Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA.
Gayathri ManiDepartment of Neurology and Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA.
Katia MaaloufDepartment of Neurology and Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Anat Stemmer-RachamimovDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
David H JungDepartment of Otolaryngology, Massachusetts Eye and Ear and Harvard Medical School, Boston, MA 02114, USA.
D Bradley WellingDepartment of Otolaryngology Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear and Massachusetts General Hospital, Boston, MA 02114, USA.
Marco GiovanniniDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center (JCCC), University of California Los Angeles, Los Angeles, CA 90095, USA.
Scott R PlotkinDepartment of Neurology and Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Casey A MaguireDepartment of Neurology, Massachusetts General Hospital and NeuroDiscovery Center, Harvard Medical School, Boston, MA 02114, USA.
Vijaya RameshDepartment of Neurology and Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Xandra O BreakefieldDepartment of Neurology and Center for Molecular Imaging Research, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Harvard University · USMassachusetts Eye and Ear Infirmary · USMassachusetts General Hospital · USUniversiti Putra Malaysia · MYUniversity of California, Los Angeles · US

Funding

Transfer of microRNA regulators from glioblastoma to brain microenvironment U19CA179563 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BREAKEFIELD, XANDRA OWENS, CHAREST, ALAIN · 2013 to 2017
$8.6M
NF2-Associated Meningiomas: From Omics Discovery to Targeted TherapyR01NS113854 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI RAMESH, VIJAYA · 2020 to 2024
$3.2M
Enhanced gene delivery for CNS and sensory disordersR01DC017117 · NIDCD · MASSACHUSETTS GENERAL HOSPITAL · PI MAGUIRE, CASEY A · 2019 to 2023
$1.8M
NCI NIH HHS U19 CA179563NIDCD NIH HHS R01 DC017117NINDS NIH HHS R01 NS113854
6 · The paper itself

Abstract

Loss of function of the neurofibromatosis type 2 (NF2) tumor suppressor gene leads to the formation of schwannomas, meningiomas, and ependymomas, comprising ∼50% of all sporadic cases of primary nervous system tumors. NF2 syndrome is an autosomal dominant condition, with bi-allelic inactivation of germline and somatic alleles resulting in loss of function of the encoded protein merlin and activation of mammalian target of rapamycin (mTOR) pathway signaling in

Indexed as

adeno-associated viral vectorgene therapyneurofibromatosis type 2Schwann cellsschwannoma

Identifiers

PMID35846573
PMCPMC9263409
OpenAlexW4283375998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.